Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Letters to the Editor

Clozapine and COVID-19

Gary Remington and Valerie Powell
J Psychiatry Neurosci July 01, 2020 45 (4) E1; DOI: https://doi.org/10.1503/jpn.2045301
Gary Remington
From the Centre of Addiction and Mental Health (CAMH) (Remington, Powell); the Campbell Family Mental Health Research Institute, CAMH (Remington); the Department of Psychiatry, University of Toronto (Remington); and the Graduate Department of Psychological Clinical Science, University of Toronto – Scarborough (Remington), Toronto, Ont., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valerie Powell
From the Centre of Addiction and Mental Health (CAMH) (Remington, Powell); the Campbell Family Mental Health Research Institute, CAMH (Remington); the Department of Psychiatry, University of Toronto (Remington); and the Graduate Department of Psychological Clinical Science, University of Toronto – Scarborough (Remington), Toronto, Ont., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

We compliment the authors and journal for ensuring the “Consensus statement on the use of clozapine during the COVID-19 pandemic” was published in a timely fashion.1 Coronavirus disease 2019 (COVID-19) rapidly transformed into a pandemic, challenging medicine in ways initially not imagined; this is certainly the case not only for treatment-resistant schizophrenia and for reasons related to clozapine, but also the patient population.2

Recommendation 1 of the consensus statement speaks to the issue of extending blood monitoring, thereby allowing individuals to stay at home and decrease the risk of exposure to COVID-19 and to the spread of the virus that causes it. The recommendation provides 3 points to guide clinicians in decision making regarding the extension of blood monitoring. The first indicates that individuals on clozapine for 1 year are eligible for extensions up to 3 months, well beyond the monthly monitoring that regulatory guidelines generally require at this point. The authors note that patients on clozapine for 6–12 months should be considered on a “case-by-case basis” and give no recommendation for change during the first 6 months of treatment. As an aside, we believe that all decisions, regardless of clozapine treatment stage and criteria, must be considered on a case-by-case basis.

The consensus statement notes that severe neutropenia (absolute neutrophil count [ANC] < 500/μL) is rare (0.009% of clozapine starts), with a case fatality rate of 2.1%.3 We would add that approximately 88% of clozapine-induced agranulocytosis cases occur in the first 6 months (unpublished data: HLS Therapeutics, 2020), meaning that the risk is considerably diminished by the time individuals are on biweekly monitoring. With these figures as background, we suggest that clinicians give consideration to this group but consider a window that is narrower; e.g., 3–4 weeks. In line with the consensus statement, we agree that those being monitored weekly continue as is, reflecting the increased risk during this time period.

The second point in Recommendation 1 relates to not extending blood monitoring for anyone who has had an ANC value < 2000/μL (or < 1500/μL if there is a history of benign ethnic neutropenia).1 To our knowledge, there is no clear relationship between such drops and actual risk of agranulocytosis, which is rare, idiosyncratic and poorly understood.3–5 Using this criterion will exclude many individuals who were not at increased risk of agranulocytosis and, for this reason, we argue against it.

Finally, any discussion of clozapine and agranulocytosis risk must be couched in a historical perspective. The reintroduction of clozapine in the 1990s with strict hematologic monitoring reflects a cluster of deaths that occurred in Finland following its initial release,6 to this day not well understood but inextricably linking clozapine and agranulocytosis. We are reminded, though, that a relationship between antipsychotics and agranulocytosis preceded clozapine, with reports dating back to the 1950s and chlorpromazine.7 Agranulocytosis has since been associated with a variety of antipsychotics as well as other psychotropics, 4 and its relationship to the former is, perhaps, best captured in a study of clozapine that concluded, “After the first year of treatment, the incidence of agranulocytosis significantly decreased to the order noted with some phenothiazines.”8

Footnotes

  • Competing interests: G. Remington has received clinical, research and advisory board support from HLS Therapeutics, consultant fees from Mitsubishi-Tanabe Pharma Corporation, and research support from the University of Toronto, Canadian Institutes of Health Research (CIHR) and Research Hospital Fund–Canada Foundation for Innovation (RHF-CFI). No other competing interests were declared.

References

  1. ↵
    1. Siskind D,
    2. Honer WG,
    3. Clark S,
    4. et al
    .Consensus statement on the use of clozapine during the COVID-19 pandemic.J Psychiatry Neurosci 2020;45200061
  2. ↵
    1. Druss BG
    .Addressing the COVID-19 Pandemic in populations with serious mental illness.JAMA Psychiatry 2020doi:10.1001/jamapsychiatry.2020.0894
    OpenUrlCrossRefPubMed
  3. ↵
    1. Myles N,
    2. Myles H,
    3. Xia S,
    4. et al
    .Meta-analysis examining the epidemiology of clozapine-associated neutropenia.Acta Psychiatr Scand 2018;138:101–9.
    OpenUrlPubMed
  4. ↵
    1. Andres E,
    2. Villalba NL,
    3. Zulfiqar AA,
    4. et al
    .State of art of diosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies.J Clin Med 2019;8:1351
    OpenUrl
  5. ↵
    1. Whiskey E,
    2. Dzahini O,
    3. Ramsay R,
    4. et al
    .Need to bleed? Clozapine haematological monitoring approaches a time for change.Int Clin Psychopharmacol 2019;34:264–8.
    OpenUrl
  6. ↵
    1. Crilly J
    .The history of clozapine and its emergence in the US market: a review and analysis.Hist Psychiatry 2007;18:39–60.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Tasker JR
    .Fatal agranulocytosis during treatment with chlorpromazine.Br Med J 1955;1:950–1.
    OpenUrlFREE Full Text
  8. ↵
    1. Atkin K,
    2. Kendall F,
    3. Gould D,
    4. et al
    .Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.Br J Psychiatry 1996;169:483–8.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of Psychiatry and Neuroscience: 45 (4)
J Psychiatry Neurosci
Vol. 45, Issue 4
1 Jul 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on JPN.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clozapine and COVID-19
(Your Name) has sent you a message from JPN
(Your Name) thought you would like to see the JPN web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clozapine and COVID-19
Gary Remington, Valerie Powell
J Psychiatry Neurosci Jul 2020, 45 (4) E1; DOI: 10.1503/jpn.2045301

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Clozapine and COVID-19
Gary Remington, Valerie Powell
J Psychiatry Neurosci Jul 2020, 45 (4) E1; DOI: 10.1503/jpn.2045301
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • Consensus statement on the use of clozapine during the COVID-19 pandemic
  • The authors respond
  • PubMed
  • Google Scholar

Cited By...

  • A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire